How We Help – TELUS Ride For Dad

Since it was founded in 2000, the TELUS Ride For Dad has donated more than $33 million to the Prostate Cancer Fight Foundation to fund research and awareness campaigns across Canada.

Your support is helping to make a difference in prostate cancer research, diagnosis and treatment! One of the main goals of the Prostate Cancer Fight Foundation and the TELUS Ride For Dad is to award research grants for new and innovative breakthrough science; research that can make a difference for persons diagnosed with prostate cancer.

Ride Year	Chapter	Project Title	Lead Researcher
2018	Yukon	Improving Prostate Cancer Diagnosis and Management in the Yukon	John Lewis, University of Alberta
2018	Windsor	Suppression of prostate-specific membrane antigen (PSMA) in poor prognostic neuroendocrine prostate cancer differentiation, imaging and therapy	Dr. Lisa A. Porter, University of Windsor, Biological Sciences
2018	Swift Current	Factors affecting Prostate Cancer outcomes in SK: a comprehensive epidemiological review	Dr. Michael Szafron, School of Public Health, University of Saskatchewan
2018	Saskatoon	Eradication of localized prostate cancer by irreversible electroporation ablation combined with immunotherapy via converting tolerogenic tumor microenvironment.	Jim Xiang, M.D., Ph.D, Department of Oncology, College of Medecine, University of Saskatchewan
2018	Ottawa	Analysis of the innate lymphocyte landscape in prostate cancer.	Michele Ardolino, Ottawa Hospital Research Institute/University of Ottawa
2018	Ottawa	The Role of Beta1 Integrin Signaling in promote bone metastatic prostate cancer growth.	Christina Addison, Ottawa Hospital Research Institute
2018	Okanagan	High Dose Rate Brachytherapy for Prostate Cancer	Dr. Juanita Crook, BC Cancer Foundation
2018	Nipissing	Factors associated with prostate cancer stage at diagnosis, treatment and survival: the effects of geographic region and rurality.	Dr. Michael Conlon PhD, Health Sciences North Research Institute, NorthEast Cancer Centre, Dr. Andrew Pearce MD, Health Sciences North Research Institute, NorthEast Cancer Centre & Dr. Ryan Carlson MD, Health Sciences North Research Institute, NorthEast Cancer Centre
2018	Niagara	Clinical and Dosimetric Effects of Peri-rectal Spacers on Erectile Function in Men Undergoing Image Guided Prostate Radiotherapy	Dr. Abhi Hallock MD FRCPC LLM, Walker Family Cancer Center, Niagara Health
2018	Montreal	Generating a population-based recurrence risk map based on PSMA-PET imaging to guide radiotherapy.	Dr. Cynthia Ménard, Centre de recherche du CHUM
2018	Moncton	Prostate cancer liquid biopsy: Plasma and urine extracellular vesicles profiles for early detection and risk stratification.	Rodney Ouellette, Atlantic Cancer Research Institute
2018	Manitoba	Lamin A/C levels in circulating tumor cells	Sabine Mai, University of Manitoba
2018	Manitoba	Identification of clinically relevant lysosomotropic agents to treat aggressive prostate cancer.	Dr. Spencer Gibson, CancerCare Manitoba
2018	London	Pre-clinical optimization and assessment of a novel blood-based circulating tumor cell (CTC) assay to differentiate between indolent versus aggressive disease.	Dr. Alison Allan, Cancer Research Laboratories Program, London Regional Cancer Program, London Health Sciences Centre; and Lawson Health Research Institute
2018	Kingston-Quinte	Testing novel IL-27-based therapies for prostate cancer	Katrina Gee, Queen's University
2018	Huronia	Pilot Study of Focal Salvage HDR Brachytherapy After Local Recurrence from Brachytherapy	Dr. Hans Chung, Sunnybrook Odette Cancer Centre
2018	Huronia	Stereotactic Body Radiotherapy for Post-Prostatectomy Patients with Localized Prostate Cancer: A Phase I Study	Chia-Lin Tseng, Sunnybrook Health Sciences Centre, University of Toronto
2018	Huronia	High Dose Rate (HDR) Brachytherapy Boost and Stereotactic Body Radiation Therapy (SBRT) for Intermediate Risk Prostate Cancer: Phase II Clinical Trial.	Yaser Hasan MD FRCPC, Sunnybrook Odette Cancer Centre, University of Toronto
2018	Huronia	Development of patient-derived prostate cancer cells for early prediction of therapy response	Stanley Liu, MD, PhD, Sunnybrook-Odette Cancer Centre
2018	Grand River	Exploring the impact of a smoking cessation program on Prostate Cancer Patients undergoing Radiation Therapy Treatment	Dr. Ernest Osei, Medical Physics Department, Grand River Hospital
2018	Grand River	PEARL: PSMA PET/CT, Evaluating its Application in Real Life (extension)	Dr. Joda Kuk, Grand River Regional Cancer Centre
2018	Edmonton	Improving the Management of Prostate Cancer using Advanced Biofluid Diagnostics	John Lewis, University of Alberta
2018	Calgary/Rural AB	Prostate-derived fibroblast ‘bystander cells’, proteinase signalling and prostate cancer cell regulation	Dr. Morley D. Hollenberg, University of Calgary Cumming School of Medicine
2018	Rural AB/Calgary	Prostate-derived fibroblast ‘bystander cells’, proteinase signalling and prostate cancer cell regulation	Dr. Morley D. Hollenberg, University of Calgary Cumming School of Medicine
2018	Avalon	Engrailed 2 as biomarker and driver of prostate cancer metastasis.	Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine
2018	Avalon	Characterization of a novel Myc-Pygo2 ribonucleoprotein complex that drives prostate cancer cell proliferation	Kenneth R. Kao, Memorial University of Newfoundland
2017	Big Rideau/Kingston-Quinte	Real time MRI fused to cone beam CT guided biopsies of the prostate: The safety and feasibility of a novel method of prostate biopsy.	Dr. Jason Izard, Department of Urology, Kingston General Hospital & Dr. Alexandre Menard, Department of Diagnostic Imaging, Kingston General Hospital
2017	Kingston-Quinte/Big Rideau	Real time MRI fused to cone beam CT guided biopsies of the prostate: The safety and feasibility of a novel method of prostate biopsy.	Dr. Jason Izard, Department of Urology, Kingston General Hospital & Dr. Alexandre Menard, Department of Diagnostic Imaging, Kingston General Hospital
2017	Huronia	Pilot Study of Focal Salvage HDR Brachytherapy After Local Recurrence from Brachytherapy	Dr. Hans Chung, Sunnybrook Odette Cancer Centre
2017	Huronia	Immune response dynamics in Gleason 9-10 patients undergoing radiotherapy: A proof of principle study	Lucas C. Mendez MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre & Stanley Liu MD, PhD, Odette Cancer Centre, Sunnybrook Health Sciences Centre
2017	Western NL/Avalon	Analysis of the interaction between the MYC oncoprotein and Pygo2 chromatin effector in prostate cancer	Dr. Kenneth Kao, Memorial University of Newfoundland
2017	Avalon/Western NL	Analysis of the interaction between the MYC oncoprotein and Pygo2 chromatin effector in prostate cancer	Dr. Kenneth Kao, Memorial University of Newfoundland
2017	Grand River	The feasibility of using DNA enzyme functionalized liposomes to sensitize hypoxic prostate cancer for radiotherapy	Dr. Runqing Jiang, PhD, MCCPM, Grand River Regional Cancer Centre; University of Waterloo; University of Guelph
2017	Grand River	Gold nanoparticles functionalized with plant-extract for targeted treatment of canine prostate cancer	Andre Fleck, MSc., MCCPM, Medical Physicist, Medical Physics Department, Grand River Cancer Centre
2017	Golden Horseshoe	Characterizing the high-risk prostate cancer patient: evaluation of clinical, oncological, and functional outcomes following robot-assisted radical prostatectomy	Bobby Shayegan, M.D., St. Joseph's Healthcare Hamilton, St. Joseph's Healthcare Foundation, McMaster University
2017	Western NL/Avalon	Engrailed 2 regulation of prostate cancer metastasis	Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine
2017	Edmonton	Improving the management of prostate cancer using advanced biofluid diagnostics	John Lewis, University of Alberta
2017	Durham	Automated and standardized quality planning for prostate cancer radiotherapy	Alejandro Berlin, MD, MSc, Radiation Medicine Program, Princess Margaret Cancer Centre & Thomas Purdie, PhD, Department of Radiation Oncology, University of Toronto
2017	Calgary	Coagulation proteinases, proteinase-activated receptors and prostate cancer progression	Morley D. Hollenberg, University of Calgary Cumming School of Medicine
2017	Avalon/Western NL	Engrailed 2 regulation of prostate cancer metastasis	Jules JE Doré, Ph.D., Memorial University of Newfoundland, Faculty of Medicine

Net proceeds from all TELUS Ride For Dad initiatives are directed to our charity, the Prostate Cancer Fight Foundation (charitable number 85133 3179 RR0001) for prostate cancer research and awareness.

Our passion is a clear and simple one. We spread our “Get Checked Message”, draw awareness and fund research for prostate cancer.

Join us in our Fight Against Prostate Cancer so that men can continue to be there for their families and friends for years to come!